| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.05. | 60 DEGREES PHARMACEUTICALS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 60 DEGREES PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 15.05. | 60 Degrees Pharmaceuticals Announces First Quarter 2026 Results | 238 | GlobeNewswire (Europe) | WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases... ► Artikel lesen | |
| 15.05. | 60 DEGREES PHARMACEUTICALS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.04. | 60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website | 3 | GlobeNewswire (USA) | ||
| 02.04. | RedChip Companies, Inc.: Infrastructure Capital and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 236 | ACCESS Newswire | ORLANDO, FL / ACCESS Newswire / April 2, 2026 / RedChip Companies will air interviews with Infrastructure Capital Advisors, LLC (NYSE:SCAP)(NYSE:PFFA)(NYSE:BNDS) and 60 Degrees Pharmaceuticals, Inc.... ► Artikel lesen | |
| 31.03. | 60 Degrees Pharmaceuticals GAAP EPS of -$11.73 misses by $4.83, revenue of $1M misses by $1.05M | 2 | Seeking Alpha | ||
| 31.03. | 60 Degrees Pharmaceuticals Announces 2025 Annual Results | 157 | GlobeNewswire (Europe) | FY 2025 net product revenues increased 65% to $1,005,000Current shelf capacity exhausted after raise of $4 million through an ATM facility WASHINGTON, March 31, 2026 (GLOBE NEWSWIRE) -- 60 Degrees... ► Artikel lesen | |
| 30.03. | 60 DEGREES PHARMACEUTICALS, INC. - 10-K, Annual Report | - | SEC Filings | ||
| 20.03. | 60 DEGREES PHARMACEUTICALS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.03. | 60 Degrees Pharma submits dietary supplement notification to FDA | 1 | Investing.com | ||
| 18.03. | 60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract | 3 | GlobeNewswire (USA) | ||
| 13.03. | 60 Degrees Pharmaceuticals legt aktualisiertes Rechtsgutachten für ATM-Aktienprogramm vor | 1 | Investing.com Deutsch | ||
| 13.03. | What's Going On With 60 Degrees Pharmaceuticals On Friday? | 1 | Benzinga.com | ||
| 12.03. | 60 DEGREES PHARMACEUTICALS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.03. | 60 Degrees meldet Heilung von drei Patienten in Babesiose-Studie | 1 | Investing.com Deutsch | ||
| 11.03. | 60 Degrees reports babesiosis cure in three trial patients | 3 | Investing.com | ||
| 11.03. | 60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial | 280 | GlobeNewswire (Europe) | All three patients enrolled in study have been cured, confirming high cure rate of tafenoquine in immunosuppressed patients, as reported by Yale in a 2024 publicationCompany calls for existing babesiosis... ► Artikel lesen | |
| 27.02. | RedChip Companies, Inc.: 60 Degrees Pharmaceuticals and BioVie Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 508 | ACCESS Newswire | ORLANDO, FL / ACCESS Newswire / February 27, 2026 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) and BioVie, Inc. (NASDAQ:BIVI) on the RedChip Small Stocks... ► Artikel lesen | |
| 24.02. | 60 Degrees Pharmaceuticals (SXTP) Partners With GoodRx to Expand Access to ARAKODA | 1 | Insider Monkey | ||
| 12.02. | 60 DEGREES PHARMACEUTICALS, INC. - 8-K, Current Report | - | SEC Filings |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 38,550 | -0,93 % | ANALYSE-FLASH: Barclays hebt Ziel für Bayer auf 50 Euro - 'Overweight' | LONDON (dpa-AFX Broker) - Die britische Investmentbank Barclays hat das Kursziel für Bayer von 48 auf 50 Euro angehoben und die Einstufung auf "Overweight" belassen. Bayer habe mit der Gewinnentwicklung... ► Artikel lesen | |
| NOVO NORDISK | 38,925 | +2,33 % | Novo Nordisk hält Boden gegen Lilly-Konkurrenz | Novo Nordisk steht bei zwei Analystenteams im Fokus. Die Verschreibungsdaten für Wegovy und die Langzeitstudie CagriSema sind die bestimmenden Themen, die Einstufungen bleiben neutral. Barclays behält... ► Artikel lesen | |
| GILEAD SCIENCES | 116,12 | +0,31 % | Gilead Gets Positive CHMP Opinion For Trodelvy In First-Line Metastatic TNBC | FOSTER CITY (dpa-AFX) - Gilead Sciences Inc. (GILD) on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended marketing authorization for Trodelvy... ► Artikel lesen | |
| AURORA CANNABIS | 2,994 | 0,00 % | Bioxyne Aktie in Hochform: Aurora-Deal und 50-Millionen-AUD-Vertrag könnten neues Wachstum entfachen | ||
| GSK | 22,190 | +0,23 % | GSK: Japan's MHLW Expands Eligible Population For Arexvy | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - GSK plc (GSK, GSK.L) announced that Japan's Ministry of Health, Labour and Welfare has expanded the eligible population for RSV vaccine, Arexvy, to include... ► Artikel lesen | |
| ABBVIE | 187,00 | +0,56 % | AbbVie's MAVIRET Secures Positive CHMP Opinion For Acute Hepatitis C Infection Treatment | WASHINGTON (dpa-AFX) - Friday, AbbVie Inc. (ABBV) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the... ► Artikel lesen | |
| ROCHE | 366,00 | -0,29 % | Roche und MPP unterzeichnen Lizenzvereinbarung für Grippemittel Xofluza | ZÜRICH (dpa-AFX) - Roche und die von der UN-unterstützte Gesundheitsorganisation Medicines Patent Pool (MPP) haben eine freiwillige Lizenzvereinbarung für das Grippemedikament Xofluza (Baloxavir Marboxil)... ► Artikel lesen | |
| CANOPY GROWTH | 0,917 | +2,37 % | Tilray, Canopy & Co. bangen: Cannabis-Aktien droht der Super-GAU: Anleger machen jetzt fatalen Fehler, wenn | © Foto: adobe.stock.comDie Uhr tickt. Der Countdown läuft. Der Cannabis-Sektor steuert auf seine ultimative Entfesselung zu oder steuert direkt ins Chaos. Zwischen diesen beiden Extremen wird es sich... ► Artikel lesen | |
| ELI LILLY | 924,40 | +0,61 % | CNBC Reports Strong Phase 3 Results for Eli Lilly's Retatrutide | ||
| ASTRAZENECA | 162,85 | +0,99 % | Nach Patent-Schock: AstraZeneca landet Milliarden-Coup mit neuem Blutdruck-Medikament | © Foto: CFOTO - picture alliance / CFOTOAstraZeneca erhält die US-Zulassung für ein neues Blutdruck-Medikament. Der Konzern setzt auf Milliardenumsätze und neue Wachstumsimpulse.Der Pharmakonzern AstraZeneca... ► Artikel lesen | |
| TILRAY BRANDS | 4,590 | +0,55 % | Brewdog founder James Watt launches 'equity punk' comeback | ||
| BRISTOL-MYERS SQUIBB | 51,71 | +0,96 % | Bristol Myers Squibb Enters Agreement With Anthropic To Deploy Claude | NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb (BMY) announced a strategic agreement with Anthropic to deploy Claude across the company's research, clinical development, manufacturing, commercial... ► Artikel lesen | |
| TEVA | 29,400 | 0,00 % | Teva: European Medicines Agency Accepts Marketing Authorization Application For TEV-'749 | PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals International GmbH, a unit of Teva Pharmaceutical Industries (TEVA), and Medincell announced that the European Medicines Agency has accepted the... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 376,10 | +0,44 % | Vertex Announces New Drug Submission for Suzetrigine Has Been Accepted for Review by Health Canada for the Treatment of Moderate-to-Severe Acute Pain in Adults | ||
| ABBOTT LABORATORIES | 75,70 | +0,50 % | Abbott Laboratories Stock Is Getting Decimated, But the Smart Money Senses Opportunity |